Key result
Early IV prostacyclin prevents infarct extension vs placebo and lowers cardiac enzymes in acute MI.
Why the study?
The potential protective effect of prostacyclin on ischaemic myocardium in patients with acute myocardial infarction was investigated.
Does intravenous prostacyclin reduce myocardial injury in patients with acute myocardial infarction?
RCT (n=30)
Does intravenous prostacyclin reduce myocardial injury in patients with acute myocardial infarction?
Intravenous prostacyclin infusion initiated within 6 hours of symptom onset may limit myocardial injury and prevent infarct extension in patients with acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Early prostacyclin limits infarct markers and extension in AMI when started <6 h; provides first human RCT evidence extending animal data but needs confirmation.
Henriksson et al. (1985) conducted an RCT in acute myocardial infarction (n=30). Prostacyclin vs. Placebo was evaluated on infarct extension during the infusion. Intravenous prostacyclin infusion significantly prevented infarct extension compared to placebo (0 vs 4 patients) and lowered cardiac enzymes when administered within 6 hours of symptom onset.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: